One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release

References

• Havu N, Maaroos HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol 1991; Suppl 186: 90–4
   Web of Science ®Google Scholar
• Solcia E, Capella C, Sessa F, Rindi G, Cornaggia M, Riva C, et al. Gastric carcinoids and related endocrine growths. Digestion 1986; 35 Suppl 1: 3–22
   PubMed Web of Science ®Google Scholar
• Ryberg B, Tielemans Y, Axelson J, Carlsson E, Håkanson R, Mattson H, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990; 99: 935–42
   PubMed Web of Science ®Google Scholar
• Håkanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993; 105: 15–21
   PubMed Web of Science ®Google Scholar
• Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl J Med 1955; 252: 1103–10
   PubMed Web of Science ®Google Scholar
• Kokkola A, Sjøblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33: 88–92
   PubMed Web of Science ®Google Scholar
• Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88: 638–48
   PubMed Web of Science ®Google Scholar
• Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104: 994–1006
   PubMed Web of Science ®Google Scholar
• Syversen U, Jacobsen MB, O'Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994; 26: 201–6
   PubMed Web of Science ®Google Scholar
• Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622–8
   PubMed Web of Science ®Google Scholar
• Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997; 32: 198–202
   PubMed Web of Science ®Google Scholar
• Waldum HL, Syversen U. Chromogranin A (CGA) and the enterochromaffin-like (ECL) cell. Adv Exp Med Biol 2000; 482: 361–7
   PubMed Web of Science ®Google Scholar
• Prinz C, Sachs G, Walsh JH, Coy DH, Wu SV. The somatostatin receptor subtype on rat enterochromaffinlike cells. Gastroenterology 1994; 107: 1067–74
   PubMed Web of Science ®Google Scholar
• Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004; 39: 621–8
   PubMed Web of Science ®Google Scholar
• Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985; 20: 569–76
   PubMed Web of Science ®Google Scholar
• Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004; 39: 969–73
   PubMed Web of Science ®Google Scholar
• Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin-like cells of the rat stomach: establishment of a dose response relationship. Gut 1992; 33: 1303–6
   PubMed Web of Science ®Google Scholar
• Bakke I, Sandvik AK, Waldum HL. Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia. J Mol Endocrinol 2000; 25: 109–19
   PubMed Web of Science ®Google Scholar
• Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993; 25: 375–91
   PubMed Web of Science ®Google Scholar
• Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 2002; 146: 295–302
   PubMed Web of Science ®Google Scholar
• Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 681–99
   PubMed Web of Science ®Google Scholar
• Plockinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990; 71: 1658–62
   PubMed Web of Science ®Google Scholar
• Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 1997; 79: 830–4
   PubMed Web of Science ®Google Scholar
• Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996; 38: 775–83
   PubMed Web of Science ®Google Scholar
• Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987; 36: 108–24
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W, Lembcke B, Folsch UR, Schleser S, Koop I. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans. Am J Med 1987; 82: 49–54
   PubMed Web of Science ®Google Scholar
• Moser AJ, Giurgiu DI, Morgenstern KE, Abedin ZR, Roslyn JJ, Abedin MZ. Octreotide stimulates Ca+ +  secretion by the gallbladder: a risk factor for gallstones. Surgery 1999; 125: 509–13
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?. Am J Gastroenterol 2004; 99: 23–32
   PubMed Web of Science ®Google Scholar
• Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994; 73: 2053–8
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Falkmer S, Westre B, Waldum HL. Clinical and histopathological tumour progression in ECL cell carcinoids (“ECLomas”). APMIS 1999; 107: 1085–92
   PubMed Web of Science ®Google Scholar
• Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532–42
   PubMed Web of Science ®Google Scholar
• Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185–200
   PubMed Web of Science ®Google Scholar
• Waldum HL, Brenna E, Sandvik AK, Syversen U, Falkmer S. Hormones and carcinogenesis. Endocrine-Related Cancer 1998; 5: 45–8
   Web of Science ®Google Scholar